TABLE 2.
Neuropathy Symptoms and Change scale (NSC), Neuropathy Impairment Score (NIS) and Neuropathy Total Symptom Score-6 (NTSS-6) in Group 1 patients [(+/−)-thioctic acid)] and in Group 2 patients [(+)-thioctic acid] at baseline (T0) and after 60 days of treatment (Tlast).Data are means ± S.D. Response rate and pain half-life data represent the percentage of patients with reduction of pain score respect to baseline after treatment (response ratio) and the days for pain half-life.
| Neuropathy symptoms and change scale (NSC), neuropathy impairment score (NIS) and neuropathy total symptom Score-6 (NTSS-6) | |||
|---|---|---|---|
| Pain scales | Group 2 (+)-thioctic acid | Group 1 (+/−)-thioctic acid | |
| NCS | T0 | 17.6 ± 5.3 | 17.2 ± 5.1 |
| Tlast | 11.3 ± 4.8*# | 13.0 ± 5.4* | |
| Reduction from baseline | 6.26 ± 4.30# | 4.12 ± 3.13 | |
| Percentage reduction | 34.4 ± 19.1# | 24.7 ± 17.3 | |
| Response rate | 94° | 84 | |
| Pain half-life | 84 | 125 | |
| NIS | T0 | 4.28 ± 4.22 | 4.30 ± 3.08 |
| Tlast | 1.94 ± 3.80* | 2.64 ± 2.99* | |
| Reduction from baseline | 2.34 ± 2.56 | 1.66 ± 1.81 | |
| Percentage reduction | 53.9 ± 44.4 | 40.2 ± 43.3 | |
| Response rate | 66 | 60 | |
| Pain half-life | 55 | 78 | |
| NTSS-6 | T0 | 3.86 ± 2.95 | 4.01 ± 2.56 |
| Tlast | 1.98 ± 2.47* | 2.65 ± 2.36* | |
| Reduction from baseline | 1.88 ± 1.96 | 1.35 ± 1.95 | |
| Percentage reduction | 53.7 ± 40.2# | 36.2 ± 39.7 | |
| Response rate | 78° | 64 | |
| Pain half-life | 62 | 89 | |
*p < 0.05 vs T0 evaluated by Student’s t-test for paired data; #p < 0.05 vs Group 1 patients evaluated by ANOVA Test; ° p < 0.05 vs. Group 1 patients, X2 test.